Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medicinal cannabis interaction study with irinotecan or docetaxel in cancer patients
NL-OMON24424Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2004
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Bedrocan, irinotecan and docetaxel in cancer (2 arms), sponsored by Erasmus MC. Primary endpoints: Irinotecan and metabolite pharmacokinetics and Docetaxel pharmacokinetics. Started Jan 2004; status: active, not recruiting.
02
Drugs
Bedrocanirinotecandocetaxel
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON24424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24424.